Skip to main content
Erschienen in: Obesity Surgery 7/2010

01.07.2010 | Economic Aspects

The Cost, Quality of Life Impact, and Cost–Utility of Bariatric Surgery in a Managed Care Population

verfasst von: Laura N. McEwen, Renuka B. Coelho, Lauren M. Baumann, Dori Bilik, Betsy Nota-Kirby, William H. Herman

Erschienen in: Obesity Surgery | Ausgabe 7/2010

Einloggen, um Zugang zu erhalten

Abstract

Our purpose was to assess the cost, quality of life impact, and the cost–utility of bariatric surgery in a managed care population. We studied 221 patients who underwent bariatric surgery between 2001 and 2005. We analyzed medical claims data for all patients and survey data for 122 survey respondents (55% response rate). Patients were generally middle-aged, female, and white. Sixty-four percent underwent open and 33% underwent laparoscopic Roux-en-Y procedures. One year after surgery, mean body mass index fell from 51 to 31 kg/m2 in women and from 59 to 35 kg/m2 in men with substantial improvements in comorbidities. Postsurgical mortality and morbidity were low. Total per member per month costs increased in the 6 months before bariatric surgery, were lower in the 12 months after bariatric surgery, but increased somewhat over the next 12 months. When presurgical quality of life was assessed prospectively, average health utility scores improved by 0.14 one year after surgery. In analyses that took a lifetime time horizon, projected future costs based on age and obesity and discounted costs and health utilities at 3% per year, the cost–utility ratio for bariatric surgery versus no surgery was approximately $1,400 per quality-adjusted life-year gained. In sensitivity analyses, bariatric surgery was more cost-effective in women, non-whites, more obese patients, and when performed laparoscopically. Although not cost-saving, bariatric surgery represents a very good value for money. Its long-term cost effectiveness appears to depend on the natural history and cost of late postsurgical complications and the natural history and cost of untreated morbid obesity.
Literatur
1.
Zurück zum Zitat Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA. 2006;295:1549–55.CrossRefPubMed Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA. 2006;295:1549–55.CrossRefPubMed
2.
Zurück zum Zitat Ahroni JH, Montgomery KF, Watkins BM. Laparoscopic adjustable gastric banding: weight loss, co-morbidities, medication usage and quality of life at one year. Obes Surg. 2005;15:641–7.CrossRefPubMed Ahroni JH, Montgomery KF, Watkins BM. Laparoscopic adjustable gastric banding: weight loss, co-morbidities, medication usage and quality of life at one year. Obes Surg. 2005;15:641–7.CrossRefPubMed
3.
Zurück zum Zitat Hensrud DD, Klein S. Extreme obesity: a new medical crisis in the United States. Mayo Clin Proc. 2006;81:S5–S10.PubMed Hensrud DD, Klein S. Extreme obesity: a new medical crisis in the United States. Mayo Clin Proc. 2006;81:S5–S10.PubMed
4.
Zurück zum Zitat NIH Technology Assessment Conference Panel. Methods for voluntary weight loss and control. Ann Intern Med. 1993;119(7 pt 2):764. NIH Technology Assessment Conference Panel. Methods for voluntary weight loss and control. Ann Intern Med. 1993;119(7 pt 2):764.
5.
Zurück zum Zitat Shekelle PG, Morton SC, Maglione M et al. Pharmacological and surgical treatment of obesity. Evidence Report/Technology Assessment No. 103 (prepared by the Southern California-RAND Evidence-based Practice Center, under Contract No. 290-02-0003). AHRQ Publication No. 04-E028-1. Rockville, MD: Agency for Healthcare Research and Quality, July 2004. Shekelle PG, Morton SC, Maglione M et al. Pharmacological and surgical treatment of obesity. Evidence Report/Technology Assessment No. 103 (prepared by the Southern California-RAND Evidence-based Practice Center, under Contract No. 290-02-0003). AHRQ Publication No. 04-E028-1. Rockville, MD: Agency for Healthcare Research and Quality, July 2004.
6.
Zurück zum Zitat Maggard MA, Shugarman LR, Suttorp M, et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med. 2005;142:547–59.PubMed Maggard MA, Shugarman LR, Suttorp M, et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med. 2005;142:547–59.PubMed
7.
Zurück zum Zitat Centers for Medicare and Medicaid Services. Medicare Coverage Database. Decision Memo for Bariatric Surgery for the Treatment of Morbid Obesity (CAG-00250R). Vol. 2006: US Department of Health and Human Services. Available at: http://www.cms.hhs.gov/mcd/viewdecisionmemo. Accessed December 3, 2008. Centers for Medicare and Medicaid Services. Medicare Coverage Database. Decision Memo for Bariatric Surgery for the Treatment of Morbid Obesity (CAG-00250R). Vol. 2006: US Department of Health and Human Services. Available at: http://​www.​cms.​hhs.​gov/​mcd/​viewdecisionmemo​. Accessed December 3, 2008.
8.
Zurück zum Zitat Sjöström L, Narbro K, Sjöström CD, et al. Swedish obese subjects study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741–52.CrossRefPubMed Sjöström L, Narbro K, Sjöström CD, et al. Swedish obese subjects study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741–52.CrossRefPubMed
9.
Zurück zum Zitat Benko LB. Weighty concerns. Mod Healthc. 2006;36:39. Benko LB. Weighty concerns. Mod Healthc. 2006;36:39.
10.
Zurück zum Zitat Freudenheim M. Hospitals pressured by soaring demand for obesity surgery. The New York Times, 29 August 2003. Freudenheim M. Hospitals pressured by soaring demand for obesity surgery. The New York Times, 29 August 2003.
12.
Zurück zum Zitat Ackroyd R, Mouiel J, Chevallier JM, et al. Cost-effectiveness and budget impact of obesity surgery in patients with type-2 diabetes in three European countries. Obes Surg. 2006;16:1488–503.CrossRefPubMed Ackroyd R, Mouiel J, Chevallier JM, et al. Cost-effectiveness and budget impact of obesity surgery in patients with type-2 diabetes in three European countries. Obes Surg. 2006;16:1488–503.CrossRefPubMed
13.
Zurück zum Zitat Salem L, Devlin A, Sullivan SD, et al. A cost-effectiveness analysis of laparoscopic gastric bypass, adjustable gastric banding and non-surgical weight loss. Surg Obes Relat Dis. 2008;4:26–32.CrossRefPubMed Salem L, Devlin A, Sullivan SD, et al. A cost-effectiveness analysis of laparoscopic gastric bypass, adjustable gastric banding and non-surgical weight loss. Surg Obes Relat Dis. 2008;4:26–32.CrossRefPubMed
14.
Zurück zum Zitat Ikramuddin S, Klingman D, Swan T, et al. Cost-effectiveness of Roux-en-Y gastric bypass in type diabetes patients. Am J Manag Care. 2009;15:607–15.PubMed Ikramuddin S, Klingman D, Swan T, et al. Cost-effectiveness of Roux-en-Y gastric bypass in type diabetes patients. Am J Manag Care. 2009;15:607–15.PubMed
15.
Zurück zum Zitat Keating CL, Dixon JB, Moodie ML, et al. Cost-effectiveness of surgically induced weight loss for the management of type 2 diabetes: modeled lifetime analysis. Diab Care. 2009;32:567–74.CrossRef Keating CL, Dixon JB, Moodie ML, et al. Cost-effectiveness of surgically induced weight loss for the management of type 2 diabetes: modeled lifetime analysis. Diab Care. 2009;32:567–74.CrossRef
16.
Zurück zum Zitat Keating CL, Dixon JB, Moodie ML, et al. Cost-efficacy of surgically induced weight loss for the management of type 2 diabetes. Diab Care. 2009;32:580–4.CrossRef Keating CL, Dixon JB, Moodie ML, et al. Cost-efficacy of surgically induced weight loss for the management of type 2 diabetes. Diab Care. 2009;32:580–4.CrossRef
17.
Zurück zum Zitat Red Book: Pharmacy’s Fundamental Reference, 2006 Edition. Thomson PDR, Montvale, NJ, 2006. Red Book: Pharmacy’s Fundamental Reference, 2006 Edition. Thomson PDR, Montvale, NJ, 2006.
19.
Zurück zum Zitat Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005;43:203–20.CrossRefPubMed Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005;43:203–20.CrossRefPubMed
20.
Zurück zum Zitat Finkelstein EA, Brown DS. Return on investment for bariatric surgery. AJMC. 2008;14:561–2. Finkelstein EA, Brown DS. Return on investment for bariatric surgery. AJMC. 2008;14:561–2.
21.
Zurück zum Zitat van Baal PHM, Polder JJ, de Wit GA, et al. Lifetime medical costs of obesity: prevention no cure for increasing health expenditure. PLoS Med. 2008;5:0242–9.CrossRef van Baal PHM, Polder JJ, de Wit GA, et al. Lifetime medical costs of obesity: prevention no cure for increasing health expenditure. PLoS Med. 2008;5:0242–9.CrossRef
23.
Zurück zum Zitat Flegal KM, Graubard BI, Williamson DF, et al. Excess deaths associated with underweight, overweight, and obesity. JAMA. 2005;293:1861–7.CrossRefPubMed Flegal KM, Graubard BI, Williamson DF, et al. Excess deaths associated with underweight, overweight, and obesity. JAMA. 2005;293:1861–7.CrossRefPubMed
24.
Zurück zum Zitat van Mastrigt GAPG, van Dielen FMH, Severens JL, et al. One-year cost-effectiveness of surgical treatment of morbid obesity: vertical banded gastroplasty versus lap-band. Obes Surg. 2006;16:75–84.CrossRefPubMed van Mastrigt GAPG, van Dielen FMH, Severens JL, et al. One-year cost-effectiveness of surgical treatment of morbid obesity: vertical banded gastroplasty versus lap-band. Obes Surg. 2006;16:75–84.CrossRefPubMed
25.
Zurück zum Zitat Sach TH, Barton GR, Doherty M, et al. The relationship between body mass index and health-related quality of life: comparing the EQ-5D, EuroQoL VAS and SF-6D. Int J Obes. 2007;31:189–96.CrossRef Sach TH, Barton GR, Doherty M, et al. The relationship between body mass index and health-related quality of life: comparing the EQ-5D, EuroQoL VAS and SF-6D. Int J Obes. 2007;31:189–96.CrossRef
26.
Zurück zum Zitat Potteiger CE, Paragi PR, Inverso NA, et al. Bariatric surgery: shedding the monetary weight of prescription costs in the managed care arena. Obes Surg. 2004;14:725–30.CrossRefPubMed Potteiger CE, Paragi PR, Inverso NA, et al. Bariatric surgery: shedding the monetary weight of prescription costs in the managed care arena. Obes Surg. 2004;14:725–30.CrossRefPubMed
27.
Zurück zum Zitat Snow LL, Weinstein LS, Hannon JK, et al. The effect of Roux-en-Y gastric bypass on prescription drug costs. Obes Surg. 2004;14:1031–5.CrossRefPubMed Snow LL, Weinstein LS, Hannon JK, et al. The effect of Roux-en-Y gastric bypass on prescription drug costs. Obes Surg. 2004;14:1031–5.CrossRefPubMed
28.
Zurück zum Zitat Craig BM, Tseng DS. Cost-effectiveness of gastric bypass for severe obesity. Am J Med. 2002;113:491–8.CrossRefPubMed Craig BM, Tseng DS. Cost-effectiveness of gastric bypass for severe obesity. Am J Med. 2002;113:491–8.CrossRefPubMed
29.
Zurück zum Zitat Clegg A, Colquitt J, Sidhu M, et al. Clinical and cost effectiveness of surgery for morbid obesity: a systematic review and economic evaluation. Int J Obes. 2003;27:1167–77.CrossRef Clegg A, Colquitt J, Sidhu M, et al. Clinical and cost effectiveness of surgery for morbid obesity: a systematic review and economic evaluation. Int J Obes. 2003;27:1167–77.CrossRef
30.
Zurück zum Zitat Crémieux PY, Buchwald H, Shikora SA, et al. A study on the economic impact of bariatric surgery. Am J Manag Care. 2008;14:589–96.PubMed Crémieux PY, Buchwald H, Shikora SA, et al. A study on the economic impact of bariatric surgery. Am J Manag Care. 2008;14:589–96.PubMed
Metadaten
Titel
The Cost, Quality of Life Impact, and Cost–Utility of Bariatric Surgery in a Managed Care Population
verfasst von
Laura N. McEwen
Renuka B. Coelho
Lauren M. Baumann
Dori Bilik
Betsy Nota-Kirby
William H. Herman
Publikationsdatum
01.07.2010
Verlag
Springer-Verlag
Erschienen in
Obesity Surgery / Ausgabe 7/2010
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-010-0169-0

Weitere Artikel der Ausgabe 7/2010

Obesity Surgery 7/2010 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.